iSpecimen Inc. (NASDAQ:ISPC – Free Report) shares are going to reverse split on the morning of Tuesday, November 24th. The 1-6 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, November 23rd.
iSpecimen Stock Down 1.0%
iSpecimen stock opened at $0.53 on Friday. The business’s 50-day simple moving average is $0.99 and its 200 day simple moving average is $3.99. The stock has a market cap of $1.33 million, a price-to-earnings ratio of -0.01 and a beta of 1.54. iSpecimen has a 12-month low of $0.47 and a 12-month high of $27.44.
iSpecimen (NASDAQ:ISPC – Get Free Report) last announced its quarterly earnings data on Tuesday, November 17th. The company reported ($1.03) EPS for the quarter. The firm had revenue of $0.24 million during the quarter. iSpecimen had a negative return on equity of 447.19% and a negative net margin of 1,796.52%.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded shares of iSpecimen from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, iSpecimen has a consensus rating of “Sell”.
Get Our Latest Analysis on ISPC
About iSpecimen
iSpecimen, Inc. operates an online marketplace that connects life-science researchers with hospitals, laboratories, biobanks and other providers of human biospecimens. Its platform is designed to help researchers find and request samples for medical and scientific research. Through its iSpecimen Marketplace, the company facilitates access to materials such as blood, tissue and other human specimens, along with associated data when available. It also supports the coordination of specimen sourcing and fulfillment between research organizations and providers.
Further Reading
- Five stocks we like better than iSpecimen
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
